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Time to endoscopic intervention in patients
with upper gastrointestinal patients can be
improved with pathway provision
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Abstract
Background: Patients with upper gastrointestinal malignancy often require admission to hospital with dysphagia or
jaundice requiring therapeutic endoscopy. Endoscopic intervention is often effective permitting rapid discharge. An
efficient service would permit rapid discharge for patients who are often at the end of life. We noted that a
majority of patients in hospital under the gastroenterological oncology were admitted with symptoms requiring
therapeutic endoscopy.
Methods: We conducted an audit cycle of the inpatient days before and after pathway implementation.
A wait of 1 day was set as acceptable for patients with bleeding as defined by NICE guidance and we set an
arbitrary standard of 2 days for patients without bleeding but requiring therapeutic endoscopy. Between the audit
cycles, a pathway was built to accommodate these patients.
Results: Inpatient waits improved from a median of 3 days to 1 day. There was no difference in outcome between
those presenting with bleeding and other symptoms or any difference in patients requiring different procedures.
Conclusions: Waiting times for endoscopy can be improved with the introduction of a targeted pathway of cancer
patients. Further issues including cost, quality of life and nutrition require further intervention.
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Background
Urgent therapeutic endoscopy is commonly needed in
patients with upper gastrointestinal (UGI) cancer.
Obstruction (oesophageal, gastric, duodenal and biliary)
and iatrogenic complications, particularly bleeding from
anti-inflammatory and anti-emetic medication are com-
mon. Most of these patients are treated with palliative
intent and prompt intervention would seem essential.
Commonly these procedures comprise oesophagoduode-
noscopy (OGD), endoscopic retrogradepancreatography
(ERCP) or another procedure such as percutaneous
endoscopic gastrostomy (PEG).
In reality, delays in therapeutic endoscopy are common,
frustrating and potentially harmful for the patient. While
waiting for a procedure, infection, thrombo-embolism and
iatrogenic or hospital acquired diarrheoa occur commonly
and weight loss while the patient remains nil-by-mouth,
commonly on more than 1 occasion, may be significant.
There is a self-evident impact on the quality of life pa-
tients with a terminal cancer diagnosis having to wait in
hospital for procedures. For some cancer patients this
time may represent a significant proportion of their
survival. Additionally, delays significantly add to hospital
costs through prolonged inpatient stays. Critically, endo-
scopic therapy is often immediately effective and leads to
prompt discharge.
NICE guidelines state that unstable patients with severe
acute UGI bleeding should be offered endoscopy immedi-
ately after resuscitation and that all other patients with
upper GI bleeding should be offered endoscopy within
24 h [1]. Cancer patients are a particularly high risk group,
with an odds ratio for mortality from upper GI bleeding of
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There are no guidelines on the optimal timing of
endoscopy for suspected GI obstruction. There have
been several studies of endoscopic intervention for
malignant obstruction, but these do not record waiting
times for procedures. Additionally the 2012 Cochrane
review on interventions for dysphagia in oesophageal
cancer found that there was no evidence base to recom-
mend the appropriate timing of self-expanding metal
stents [2].
We performed a completed audited cycle of local prac-
tice for cancer patients having upper GI endoscopy in a
central London teaching hospital practice and describe
the outcome following targeted intervention.
Methods
The audit cycle was performed at a central London
teaching hospital. All patients were in specialist oncology
beds and the gastroenterology team were contacted to
consult.
We searched electronic ward archives to identify
patients admitted under the UGI oncology team having
an endoscopy. The initial audit period was 20/11/10 to
31/07/11, and the re-audit period 01/01/2014 to 31/07/
2014. Endoscopy reports including date of procedure
were recovered from the electronic patient record sys-
tem. At the time of the initial audit endoscopy referrals
were not recorded, so waiting time was calculated from
the date when endoscopy request was first documented
in the electronic ward archive. At the time of the re-
audit endoscopy referrals were recorded, so the date of
referral was taken from endoscopy records. For patients
with suspected UGI bleeding we used an audit standard
of 1 day to wait for an OGD, as per the NICE guidelines.
For patients with non-bleeding indications for endos-
copy there is no national standard for waiting time. For
cost analysis purposes we set a ‘reasonable waiting time’
for inpatient endoscopy for non-bleeding patients of
2 days, based on consensus opinion of the investigators.
For patients identified as outliers in the data set, the
paper notes were recovered from patient records and
reviewed to identify reasons for delays.
Median waiting times were compared with the Mann
Whitney U test. Demographic differences were com-
pared with the chi-squared test. Rates of compliance
with the audit standard as well as differences in endos-
copies carried out within a specified time period were
compared with Fischer’s Exact Test.
As part of the audit cycle, following the review of
findings from the preliminary audit and prior to the re-
audit, a number of recommendations were proposed
and implemented. Firstly, a visual pathway tool was de-
veloped with the intention of providing a leaner process
and greater clarity for teams involved in the referral
procedure. Depending on patient eligibility, this also
included a day case option for the endoscopic proced-
ure. (prior to this, such patients were routinely admit-
ted) .The pathways (Additional file 1: Figure S1 and
Additional file 2: Figure S2) were devised following a
scoping exercise to review existing practice involving
medical, nursing and administrative staff from both on-
cology and gastroenterology specialties. The wider team
were also consulted during the drafting of the new
pathway. To launch and facilitate the smooth initi-
ation of the pathway, copies of the template were
disseminated and a series of teaching sessions were
carried out. Secondly, a standard time from request to
endoscopic procedure for oncology ‘non-bleeding’
cases was agreed at two working days and thirdly a
standard time from request to patient review by the
gastroenterology medical team for oncology inpatients
was agreed at 24 h.
This was an audit therefore no ethics approval was
required.
Results
For the initial audit period and re-audit, we identified 30
and 42 patients respectively who had inpatient endoscopy
during the audit periods. In both samples, oesophageal
cancer was the most common primary, obstructive symp-
toms the most common indication. The variation in pri-
mary cancer diagnosis was wider in the initial audit, with
three primaries that were not seen in the re-audit period:
cholangiocarcinoma, duodenal cancer and cancer of un-
known primary, however there were no significant statisti-
cally differences in primary tumour site between initial
audit and re-audit groups. There were also no significant
statistically differences in indication for endoscopy within
the two groups. Table 1 summarises the patients by cancer
diagnosis and indication for the procedure.
The median wait time for endoscopy was significantly less
in the re-audit group, with median wait times falling from
3 days (IQR 1.25–5 days) to 1 day (IQR 1–4.5 days;
p = 0.010) (Table 1 and Fig. 1). There were also significantly
more patients having their endoscopy performed within
24 h in the re-audit group (26.7% vs. 57.1%; p = 0.16).
In the initial audit group there was clear pattern for
waiting time differences between patients with different
primary cancer sites (Table 2). Though those with cholan-
giocarcinoma appeared to have shorter waiting times this
was no significant when compared to the rest of the co-
hort (p = 0.11). Similarly there were no significant differ-
ences in wait times between those with oesophagogastric
cancer (the largest groups in the initial audit) compared
with non-oesophagogastric cancer (p = 0.62 and 0.80 re-
spectively). In the re-audit group there were also no clear
differences in wait times between patients with different
primary cancer sites. When comparing wait times in those
with gastric, GOJ and oesophageal cancer to the rest of
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the re-audit cohort no significant differences were found
(p = 0.065, 0.79 and 0.32 respectively).
When comparing median wait times by primary cancer
site between the initial and re-audit groups a significant
reduction in wait times in those with gastric cancer was
found (median wait 4 vs. 1 days; p = 0.029). There was
also a trend for reduced wait times in both patients with
oesophageal and GOJ cancer but these did not reach
significance (p = 0.074 and 0.23 respectively, Table 2).
In the initial audit period there were no significant
difference between those who endoscopies were per-
formed for bleeding issues compared to those who did
not have bleeding problems (median wait 2 vs 3 days;
p = 0.35). In the re-audit group there was more of a
trend for patients with bleeding symptoms to have their
endoscopies performed more quickly compared to the
rest of the group (1 vs 1.5 days) but these results were
not significant (p = 0.09).
Comparing wait times between the audit groups a
significant reduction in wait times was seen in those
with bleeding symptoms (median wait 2 vs 1 days,
p = 0.04). A similar trend was also seen in those with
obstructive symptoms all this did not quite reach signifi-
cance (p = 0.051, Table 2). There was no clear pattern
for differences in waiting times by primary cancer or
procedure type.
For patients with suspected GI bleeding, compliance
with the audit standard was higher in the re-audit group
than the initial audit (88% vs 44% respectively), though
this did not reach statistical significance (p = 0.13). For
patients with obstructive symptoms significantly more
patients had their endoscopies within 24 h in the re-
audit group compared to the initial group (51.6% vs.
21.1%; p = 0.042). However there was no significant
increase in the percentage patients having their endosco-
pies for obstructive symptoms by 48 h post request
(60.6% vs 42.1%; p = 0.25).
Cost implications
The percentage of patients having endoscopy (for any in-
dication) beyond the reasonable waiting time of 48 h was
58% in the initial audit and 45% in the re-audit, with a
total cumulative number of days waited beyond 48 h of 84
and 64 respectively. With a cost of each bed day in our
oncology wards of £325, the extra waiting times accounted
for £27,300 in the initial audit and £20,800 in the re-audit
period. When adjusted for the differences in sample size,
the money lost to extra waiting was £9374 lower in the re-
audit period or approximately £120/month. This does not
include additional costs of end of life inpatient care.
Outliers
In order to try and describe common reasons for longer
delays, we reviewed the notes of the 5 patients who waited
Table 2 Median wait times for endoscopy pre and post
intervention stratified by primary tumour site and indication
for endoscopy
Median wait times (days) p-value
Pre-intervention Post-intervention
Tumour site
Gastric 4.0 1.0 0.029
Oesophageal 3.5 1.5 0.074







Bleeding 2.0 1.0 0.04
Obstructive symptoms 3.0 1.0 0.051
Other 8.5 5
GOJ – gastro-oesophageal junction, CUP – cancer of unknown primary
Table 1 Initial audit and re-audit groups by wait times for
endoscopy as well as diagnosis and indication for endoscopy
(‘Other’ indications were abdominal pain, broncho-oesophageal
fistula, acute diarrhoea, abdominal pain, and one documented
only as ‘diagnostic’)
Initial audit Re-audit P value
Total no. Endoscopies 30 42
Median wait (days) 3 1 0.010
IQR (days) 3.8 3.5
% done within 24 h 26.7 57.1 0.016
% done within 48 h 43.3 61.9 0.096
Tumour site N (%) N (%)
CUP 2 (6.7) 0 0.06
Cholangiocarcinoma 3 (10) 0
Colorectal 1 (3.3) 3 (7.1)
Duodenal 2 (6.7) 0
Gastric 4 (13.3) 5 (11.9)
GOJ 2 (6.7) 5 (11.9)
Oesophageal 16 (53.3) 26 (61.9)
Pancreas 0 3 (7.1)
Indication (%) N (%) N (%)
Bleeding 9 (30) 8 (19) 0.33
Obstructive symptoms 19 (63.3) 33 (78.6)
Other 2 (6.7) 1 (2.4)
CUP – cancer of unknown primary, GOJ – gastro-oesophageal junction
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longest (Additional file 3: Table S1). The recurring themes
for all 5 patients were a lack of resource in gastroenter-
ology department, and communication issues between on-
cology and gastroenterology. Some patients waited over a
week for an individual consultant to place a feeding tube.
Outliers were fewer in the re-audit. One patient with UGI
bleed (oesophageal cancer) waited for 6 days. The patient
had malaena and coffee ground vomiting post oesophageal
stent insertion but the haemoglobin was stable and the
gastroenterology team felt the patient did not need an ur-
gent OGD. One patient waited 14 days with obstructive
symptoms (oesophageal cancer) but during this period
was unwell on intensive care.
Discussion
We performed a retrospective audit of endoscopy proce-
dures in oncology patients in a London teaching
hospital. The median waiting time was improved from a
median of 3 days to 1 day. This was achieved through
the establishment of pathways for the common pre-
sentations and increased awareness amongst the team
coordinating therapeutic endoscopy.
The impact of waiting for procedures as an impatient is
self-evident and only partly quantifiable. If we consider
that our population was being treated with palliative in-
tent, it would be reasonable to consider their management
as end of life care. Because of the efficacy of endoscopic
intervention, prompt discharge would have been antici-
pated. End of life care in hospital is more costly than com-
munity management [3, 4] but we did not formally
evaluate this. Less quantifiable outcomes include the im-
pact on quality of life (QL) on cancer patients. Data from
patients with an UGI bleed suggest a significant impact on
QL [5]. Subsequent studies should aim to evaluate QL
and the cost-economic impact in greater detail.
Our audit assessed oncology patients admitted under
their oncology team in a cancer centre. For patients who
are admitted to a cancer unit, the pathway may differ,
with admission under the care of the acute oncology ser-
vice or the gastroenterological service. We are not aware
that this audit has been performed for patients admitted
under a different model. As such, the key aspects of the
pathway introduction was education and experience of
using the pathway. Several educational events were given
and the policy widely circulated amongst key staff
including clinical nurse specialists, appointments clerks
and endoscopists. The process became standard shortly
after introduction.
The sustainability of improvement following audit has
been identified as an issue [6]. The improvements in our
service were established by education and introduction of
a defined identity and pathway for cancer patients requir-
ing therapeutic endoscopy. The longevity of this improve-
ment will have to be determined by future audits.
The strengths of our audit were the simplicity and re-
audit after intervention. The weaknesses include a lack
of depth of data and the relatively small sample size. We
were not able to examine whether pathway implementa-
tion resulted in fewer admissions. Further issues with re-
spect to the costs, the quality of life and the nutritional
status of our patients have been identified and merit
further investigation.
Conclusions
We conducted an audit cycle to determine the effect
of a specific pathway for cancer patients waiting for
therapeutic endoscopy as inpatients. An improvement
in outcome was found suggesting that identification
of cancer patients requiring therapeutic endoscopy
may be helpful.
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